Detalhe da pesquisa
1.
Tyrosine kinase inhibitor cabozantinib impacts dendritic and natural killer cells immune response in C38 syngeneic tumor model.
Eur J Immunol
; 53(6): e2250186, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37056029
2.
Statistical classification of treatment responses in mouse clinical trials for stratified medicine in oncology drug discovery.
Sci Rep
; 14(1): 934, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195626
3.
On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models.
Cancer Res Commun
; 3(1): 140-147, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36968232
4.
NTSR1 glycosylation and MMP dependent cleavage generate three distinct forms of the protein.
Sci Rep
; 13(1): 4663, 2023 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36949141
5.
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer.
Oncol Ther
; 11(1): 111-128, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36645622
6.
Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.
Mol Cancer Ther
; 21(7): 1149-1159, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35500018
7.
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours.
Pharmaceuticals (Basel)
; 15(9)2022 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36145306
8.
Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Clin Cancer Res
; 14(4): 1258-65, 2008 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18281561
9.
DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Clin Cancer Res
; 14(7): 2145-53, 2008 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18381956
10.
A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Life Sci Alliance
; 2(4)2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31431473
11.
Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
J Med Chem
; 49(23): 6908-16, 2006 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-17154520
12.
Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.
Oncoimmunology
; 5(6): e1145333, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27471612
13.
STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.
PLoS One
; 8(12): e80305, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24324595